WO2014145857A1 - Ciblage thérapeutique de la voie mtor dans des affections neurologiques - Google Patents

Ciblage thérapeutique de la voie mtor dans des affections neurologiques Download PDF

Info

Publication number
WO2014145857A1
WO2014145857A1 PCT/US2014/030693 US2014030693W WO2014145857A1 WO 2014145857 A1 WO2014145857 A1 WO 2014145857A1 US 2014030693 W US2014030693 W US 2014030693W WO 2014145857 A1 WO2014145857 A1 WO 2014145857A1
Authority
WO
WIPO (PCT)
Prior art keywords
cntnap2
mice
kinase inhibitor
mtor
mtor kinase
Prior art date
Application number
PCT/US2014/030693
Other languages
English (en)
Inventor
Maria Karayiorgou
Sander MARKX
Joseph A. Gogos
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Priority to EP14762460.5A priority Critical patent/EP2968317A4/fr
Publication of WO2014145857A1 publication Critical patent/WO2014145857A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

La présente invention concerne des méthodes de traitement de diverses maladies neuro-développementales et neuropsychiatriques, lesdites méthodes de traitement faisant appel à l'inhibition de la voie mTOR, en particulier à l'aide d'inhibiteurs de la mTOR kinase. Ladite invention concerne des méthodes de traitement de sujets atteints de troubles neurodéveloppementaux et/ou neuropsychiatriques, lesdites méthodes consistant à administrer au sujet un agent qui inhibe la voie mTOR. De préférence, l'inhibiteur de la voie mTOR est un inhibiteur de la mTOR kinase tel que WYE 125132 et des composés analogues. Des sujets peuvent être soumis à des tests afin de déterminer s'ils sont porteurs d'une variation du nombre de copies ou d'une mutation de CNTNAP2 et, si la présence d'une telle variation du nombre de copies ou d'une telle mutation est déterminée, un traitement avec un inhibiteur de voie mTOR peut être initié.
PCT/US2014/030693 2013-03-15 2014-03-17 Ciblage thérapeutique de la voie mtor dans des affections neurologiques WO2014145857A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14762460.5A EP2968317A4 (fr) 2013-03-15 2014-03-17 Ciblage thérapeutique de la voie mtor dans des affections neurologiques

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361794606P 2013-03-15 2013-03-15
US201361852150P 2013-03-15 2013-03-15
US61/852,150 2013-03-15
US61/794,606 2013-03-15
US201361803977P 2013-03-21 2013-03-21
US61/803,977 2013-03-21
US201361918307P 2013-12-19 2013-12-19
US61/918,307 2013-12-19

Publications (1)

Publication Number Publication Date
WO2014145857A1 true WO2014145857A1 (fr) 2014-09-18

Family

ID=51538117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/030693 WO2014145857A1 (fr) 2013-03-15 2014-03-17 Ciblage thérapeutique de la voie mtor dans des affections neurologiques

Country Status (2)

Country Link
EP (1) EP2968317A4 (fr)
WO (1) WO2014145857A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015192658A1 (fr) * 2014-06-20 2015-12-23 中国科学院合肥物质科学研究院 Nouvel inhibiteur de la tyrosine kinase de bruton
US9701727B2 (en) 2011-06-29 2017-07-11 The Trustees Of Columbia University In The City Of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
CN112237629A (zh) * 2019-07-16 2021-01-19 温州市中心医院 ERK/mTOR信号通路调节剂在制备改善或治疗神经发育障碍相关疾病药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101602B2 (en) * 2006-08-23 2012-01-24 Kudos Pharmaceuticals, Ltd. Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US20120190676A1 (en) * 2009-07-23 2012-07-26 Nathaniel Moorman Inhibitors of mtor kinase as anti-viral agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062681A2 (fr) * 2008-10-30 2010-06-03 University Of South Florida Lutéoline et diosmine/diosmétine en tant que nouveaux inhibiteurs de stat3 destinés à traiter l'autisme
CN102348798A (zh) * 2009-01-16 2012-02-08 麻省理工学院 孤独症谱系障碍的诊断和治疗
CN102488687A (zh) * 2011-12-22 2012-06-13 武汉大学 雷帕霉素在制备治疗精神分裂症中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101602B2 (en) * 2006-08-23 2012-01-24 Kudos Pharmaceuticals, Ltd. Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US20120190676A1 (en) * 2009-07-23 2012-07-26 Nathaniel Moorman Inhibitors of mtor kinase as anti-viral agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CURATOLO, P ET AL.: "mTOR Inhibitors in Tuberous Sclerosis Complex.", CURRENT NEUROPHARMACOLOGY., vol. 10, 1 January 2012 (2012-01-01), pages 404 - 415, XP055279192 *
EHNINGER, D ET AL.: "From mTOR to Cognition: Molecular and Cellular Mechanisms of Cognitive Impairments in Tuberous Sclerosis.", JOURNAL OF INTELLECTUAL DISABILITY RESEARCH., vol. 53, no. 10, 1 October 2009 (2009-10-01), pages 838 - 851, XP055279189, DOI: 10.1111/J.1365-2788.2009.01208.X *
See also references of EP2968317A4 *
YU , K ET AL.: "Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2.", CANCER RESEARCH, vol. 70, no. 2, 15 January 2010 (2010-01-15), pages 621 - 631, XP002646841, DOI: 10.1158/0008-5472.CAN-09-2340 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701727B2 (en) 2011-06-29 2017-07-11 The Trustees Of Columbia University In The City Of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
WO2015192658A1 (fr) * 2014-06-20 2015-12-23 中国科学院合肥物质科学研究院 Nouvel inhibiteur de la tyrosine kinase de bruton
US9814709B2 (en) 2014-06-20 2017-11-14 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Bruton's tyrosine kinase inhibitor
CN112237629A (zh) * 2019-07-16 2021-01-19 温州市中心医院 ERK/mTOR信号通路调节剂在制备改善或治疗神经发育障碍相关疾病药物中的应用

Also Published As

Publication number Publication date
EP2968317A1 (fr) 2016-01-20
EP2968317A4 (fr) 2016-12-28

Similar Documents

Publication Publication Date Title
Bacon et al. Brain-specific Foxp1 deletion impairs neuronal development and causes autistic-like behaviour
Painter et al. Diminished Schwann cell repair responses underlie age-associated impaired axonal regeneration
Karayannis et al. Cntnap4 differentially contributes to GABAergic and dopaminergic synaptic transmission
Crestani et al. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues
Koh et al. Selective GABAA α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment
Tsai et al. Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex
Veenstra-VanderWeele et al. Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments
Chen et al. CREB binding protein is required for both short-term and long-term memory formation
Squillace et al. Dysfunctional dopaminergic neurotransmission in asocial BTBR mice
Sundberg et al. Cerebellar development and autism spectrum disorder in tuberous sclerosis complex
Wu et al. Cell cycle inhibition limits development and maintenance of neuropathic pain following spinal cord injury
Peng et al. The autism-associated MET receptor tyrosine kinase engages early neuronal growth mechanism and controls glutamatergic circuits development in the forebrain
Sragovich et al. The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse
Davis et al. Tuberous sclerosis: a new frontier in targeted treatment of autism
VanGuilder et al. Hippocampal expression of myelin‐associated inhibitors is induced with age‐related cognitive decline and correlates with deficits of spatial learning and memory
Judson et al. Decreased axon caliber underlies loss of fiber tract integrity, disproportional reductions in white matter volume, and microcephaly in Angelman syndrome model mice
Wei et al. Inhibition of IL-6 trans-signaling in the brain increases sociability in the BTBR mouse model of autism
Xie et al. Modulation of the p75 neurotrophin receptor suppresses age-related basal forebrain cholinergic neuron degeneration
Colon-Perez et al. Functional connectivity, behavioral and dopaminergic alterations 24 hours following acute exposure to synthetic bath salt drug methylenedioxypyrovalerone
Moriguchi et al. Reduced expression of Na+/Ca2+ exchangers is associated with cognitive deficits seen in Alzheimer's disease model mice
McMahon et al. Seizure-dependent mTOR activation in 5-HT neurons promotes autism-like behaviors in mice
Provenzano et al. Genetic control of social behavior: Lessons from mutant mice
US20160089377A1 (en) Therapeutic targeting of the mtor pathway in neurodevelopmental and neuropsychiatric disease
Andersen et al. Juvenile methylphenidate modulates reward‐related behaviors and cerebral blood flow by decreasing cortical D3 receptors
WO2014145857A1 (fr) Ciblage thérapeutique de la voie mtor dans des affections neurologiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14762460

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014762460

Country of ref document: EP